Document is current
Any future updates will be listed below
-
Authors
Portale, Federica
Carriero, Roberta https://orcid.org/0000-0001-8619-6152
Iovino, Marta
Kunderfranco, Paolo https://orcid.org/0000-0003-3636-3391
Pandini, Marta
Marelli, Giulia
Morina, Nicolò
Lazzeri, Massimo https://orcid.org/0000-0002-4411-3715
Casale, Paolo
Colombo, Piergiuseppe
De Simone, Gabriele
Camisaschi, Chiara
Lugli, Enrico https://orcid.org/0000-0002-1964-7678
Basso, Gianluca
Cibella, Javier
Marchini, Sergio
Bordi, Matteo https://orcid.org/0000-0001-8207-8546
Meregalli, Greta
Garbin, Anna
Dambra, Monica
Magrini, Elena https://orcid.org/0000-0003-1507-2325
Rackwitz, Wiebke
Cecconi, Francesco
Corbelli, Alessandro
Fiordaliso, Fabio https://orcid.org/0000-0002-0172-4030
Eitler, Jiri
Tonn, Torsten https://orcid.org/0000-0001-9580-2193
Di Mitri, Diletta
- License Information
-
More Information
Article History
Received: 18 December 2023
Accepted: 5 November 2024
First Online: 28 November 2024
Competing interests
: T. Tonn is named as an inventor on patents in the field of cancer immunotherapy. The remaining authors declare no competing interests.
: This study adheres to the principles outlined in the Declaration of Helsinki and the ethical standards set by our Institution. All human participants provided informed consent, and animal experiments were conducted with approval from the Institutional Animal Care. We promote diversity, equity, and inclusion in research, and we have disclosed any potential conflicts of interest.
